The scarcity of actionable mutations in mesothelioma limits the application of targeted drug treatments, and therefore, many trials have focussed on pathways affected by genetic alterations affecting BAP1, CDKN2A and NF2 (reviewed in [35]). The gene discussed is BAP1; the disease is mesothelioma.